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tips toward hypercoagulability, which may be due to alterations in factor VIII, protein C, (6) or a decrease in fibrinolysis via elevated plasminogen activator inhibitor-1. (7) Indeed, an association between NASH and portal vein thrombosis (PVT) is illustrated in the literature, (8, 9) with an increased risk of PVT in NASH patients with cirrhosis presenting for LT. (9) Similarly, obesity is a well-known risk factor for vascular thrombosis, (3, 4) and along with diabetes, (8) it has been shown to be an independent risk factor for the development of pretransplant PVT among LT recipients. (8, 10) Alone, PVT is an increasingly recognized complication of cirrhosis and is often incidentally detected either with advances in noninvasive liver imaging, in the setting of hepatic decompensation, or even during the LT procedure. (11) The prevalence of PVT in patients with cirrhosis presenting for LT has had an increasing trajectory ranging from 2% to 26%. (12) However, in the setting of an inherent proinflammatory/prothrombotic state, NASH patients with cirrhosis have an increased predilection for PVT. (9) PVT can pose technical challenges during LT depending on the degree and extent of occlusion and can lead to further problems after transplant. Restoration of portal blood flow to the allograft is crucial for recovery of liver function and is a requisite condition for successful transplantation. (11, 12) Although data suggest that posttransplant outcomes are inferior among recipients who had PVT prior to or at transplantation, (13) (14) (15) (16) there is not complete consensus because some literature indicates similar or no difference in posttransplant outcomes among recipients with and without pretransplant PVT. (10, 17, 18) Furthermore, little is currently known about the impact of pretransplant PVT and posttransplant outcomes in NASH recipients.
Because the outcomes of patients with PVT has not been well established, we wanted to see if the presence of PVT in the NASH population influences graft and patient survival outcomes. To address this knowledge gap, we aimed to investigate the association of PVT with posttransplant graft and all-cause mortality using a large nationally representative US cohort of LT recipients transplanted for liver failure secondary to NASH. We hypothesized that NASH recipients with PVT, independent of comorbidities, will have significantly higher graft failure and all-cause mortality risk after LT.
Patients and Methods

DATA sOURCE AND COHORT DEFINITION
Data on all LT recipients aged 18 years and older who underwent transplantation during January 2002 to June 2013 were obtained from the United Network for Organ Sharing (UNOS)-Standard Transplant Analysis and Research (STAR) data set as the source population. For patients with multiple LTs, only data from the first transplant were used in the analysis. Individuals who were reported by individual centers to have NASH and/or cryptogenic cirrhosis, the latter with a body mass index (BMI) ≥30 kg/m 2 , as an indication were included in the source population. We included cryptogenic cirrhosis in our study population because this was previously a term used for NASH cirrhosis. Specifically, we used the diagnosis code 4213 to identify patients with cryptogenic cirrhosis and included those with cryptogenic cirrhosis who had a BMI ≥30 kg/m 2 . Additionally, we used the diagnosis code 4214 to identify those with NASH. We excluded patients with unknown PVT status, patients who had a diagnosis of hepatocellular carcinoma (HCC), patients who received a living donor transplant, and patients who received a transplant from split-liver donors, non-heart-beating donors, or multiorgan transplants. The following variables were considered abnormal and treated as missing values: donor age <10 or >75 years old, cold ischemia time <1 or >24 hours, BMI of <15 or >55 kg/m 2 , serum albumin <0.5 or >6 g/dL, total bilirubin <0. >50 mg/dL, or a creatinine level of <0.1 or >15 mg/dL. We used PVT at listing or registration to indicate patients who had a history of PVT. PVT at time of transplant was the primary variable of interest.
COvARIATEs
Data from the UNOS-STAR source were used to determine recipients' baseline demographic characteristics at the time of LT. Information on comorbidities and laboratory values at the time of LT were also extracted from the UNOS-STAR database. Donor-and transplantation-related data were also culled from this data source. The donor risk index (DRI) was calculated based on a previously published formula. (19) 
OUTCOmE AssEssmENT
The primary outcomes of interest were graft survival and all-cause mortality after LT. All-cause mortality data, censoring events, and associated dates were obtained from UNOS-STAR data files. For the all-cause death analysis, the start of the follow-up period was the date of LT, and patients were followed until death or other censoring events, including loss to follow-up or retransplantation.
sTATIsTICAL ANALYsIs
Baseline recipient characteristics were summarized according to data at the time of LT and presented as percentages for categorical variables and mean ± standard deviation (SD) or median and interquartile range (IQR) for continuous variables. Continuous variables were compared using Student t test or the KruskalWallis test, and categorical variables were analyzed with the chi-square test.
The association between PVT categories and allcause mortality after LT was assessed using unadjusted and adjusted Cox proportional regression analysis and Kaplan-Meier plots with log-rank test. Patients' overall survival at 90 days and 1, 5, and 10 years was estimated. Then, univariate Cox proportional regression modeling was used to further evaluate the impact of PVT on patients' survival. We also conducted a multivariate Cox regression analysis, which included the potential confounding factors in the model (age, sex, race, diabetes status, BMI, serum bilirubin, and DRI). Graft failure was analyzed in the same way as all-cause mortality.
Patients who died within 90 days after LT were considered early deaths in the study. A univariate logistic regression was conducted to evaluate the impact of PVT on patients' early death. We also conducted a multiple logistic regression, which included age, sex, race, diabetes status, BMI, serum bilirubin, and DRI in the model. Early graft loss was defined as the patients who had a graft loss within 90 days after initial LT. The early graft loss was also analyzed using both univariate and multivariate logistic regression in a similar fashion as early death.
Reported P values were 2-sided and reported as significant at <0.05 for all analyses. All analyses were conducted using SAS, version 9.4 (SAS, Cary, NC). The institutional review boards of the University of Tennessee Health Science Center and the University of Memphis approved the study with exemption for informed consent.
Results
A total of 60,394 adult LT recipients who received a LT during January 2002 to June 2013 were included in our analysis. The algorithm for the cohort definition is given in Fig. 1 . After excluding patients with HCC, grafts from living or split donors, grafts from nonheart-beating donors, and multiorgan transplants, the final cohort was 40,026. Among these, 3749 NASH LT recipients were identified. Of these, there were 957 transplant recipients with a diagnosis code of 4214 with a BMI ≥30 kg/m 2 , 2409 transplant recipients with a diagnosis code of 4214, and 383 were identified by free text. Among 3749 NASH LT recipients, there were 450 PVT patients, 3239 non-PVT patients, and 60 patients with unknown PVT status, the latter of which were excluded. The final study population is 3689 with a PVT prevalence among NASH recipients of 12.2%.
The demographic and clinical characteristics of these patients are shown in Table 1 . Patients with PVT at the time of transplant were significantly older (58.5 ± 8.2 versus 57.5 ± 8.4 years old; P = 0.02), were more likely to be males (62.2% versus 54.5%; P = 0.002), were more likely to have diabetes (58.2% versus 49.4%; P < 0.001), and were more likely to be obese with a BMI ≥30 kg/m 2 (77.1% versus 71.8%; P = 0.02). There were no significant differences in Model for End-Stage Liver Disease (MELD) score, although patients with PVT had a significantly lower ORIGINAL ARTICLE | 71 bilirubin (3.6 versus 4.3 mg/dL; P < 0.001). There were no significant differences in DRI or donor characteristics between PVT patients and non-PVT patients.
In general, NASH recipients with PVT had lower graft and patient survival than NASH recipients without PVT ( Table 2) . At 90 days, NASH recipients with PVT had lower graft survival (89.3% versus 92.7%) and overall survival (92.9% versus 94.3%). The same trend held true at 1, 5, and 10 years. Variables that were statistically or clinically significant from univariate analysis were used to create a multivariate regression model evaluating graft failure and mortality at 90 days (Table 3 ). In transplant recipients with NASH, the strongest risk factor independently associated with graft failure at 90 days was the presence of a PVT (odds ratio [OR], 1.45; 95% confidence interval [CI], 1.04-2.03; P = 0.03). Age and serum bilirubin were also significantly associated with inferior graft survival at 90 days following transplantation in NASH recipients. However, when evaluating patient survival at 90 days, only age and serum bilirubin were statistically significant.
In a multivariate Cox regression model, the presence of PVT was the strongest predictor of graft failure (hazard ratio [HR], 1.37; 95% CI, 1.15-1.63; P < 0.001) and patient mortality (HR, 1.31; 95% CI, 1.09-1.58; P < 0.001; Table 4 ). Age and serum bilirubin were also independently associated with graft failure and the hazard of mortality, but the DRI was only associated with graft failure. Although the presence of diabetes was noted to increase graft failure and patient death on unadjusted analysis, this did not hold true in the adjusted model.
The presence of PVT at transplant in NASH recipients had a negative effect on graft ( Fig. 2A ) and patient survival (Fig. 2B) . The most common reason for death within 90 days among all patients was infection (55 recipients or 25.7%), followed by cardiovascular complications (53 patients or 24.8%) and graft failure (32 recipients or 15%). However, graft failure as a cause of death was most striking when comparing those with and without PVT. There was an increased percentage of patients with PVT who died of graft failure compared with recipients without PVT at transplant (14.6% versus 9.2%), which was notable at 90 days (26.7% versus 13%) as well as at 1 year (17.2% versus 12%).
Furthermore, we evaluated the interaction of PVT at listing, which we identified as PVT history with the occurrence of PVT at transplant on graft (Fig. 3A) and patient survival (Fig. 3B ). NASH recipients who had a history of PVT but had no PVT identified at the time of transplant (PVT-hx+/PVT-tx-) and those with both a PVT history and PVT noted at transplant (PVT-hx+/PVT-tx+) had inferior survival. However, the recipients with PVT-hx+/PVT-tx-had the worst graft and patient survival outcomes early on in the posttransplant period. Recipients who developed PVT between listing and transplantation (PVT-hx-/ PVT-tx+) had superior graft and patient survival compared with those who had a PVT history and PVT noted at transplant (PVT-hx+/PVT-tx+).
Discussion
In this large national cohort of US LT recipients with NASH, PVT was highly prevalent (12%), and there was a robust association between PVT at transplant with graft and all-cause mortality after LT independent of demographics (age, sex, and race), comorbidities (diabetes and BMI), and donor-related indices. The prevalence of PVT in our population is similar to that reported in the literature, which is approximately 9.7% ± 4.5%. (20) A key finding in our study is that the presence of PVT at transplant in NASH patients with cirrhosis resulted in inferior 90-day and overall graft and patient survival. Multiple studies report conflicting results in terms of the presence of PVT and posttransplant outcomes. However, many of these studies are plagued with heterogeneous study populations, with much of the literature including recipients transplanted for primary liver tumors in their 
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population. (10, 13, 14, (16) (17) (18) 21) We excluded these patients in our population to avoid any potential bias of HCC or cholangiocarcinoma. This study demonstrates PVT in patients transplanted for NASH has an outcome disadvantage early on in the posttransplant period. Not surprising, the difference in graft loss was more striking compared with patient survival, as patients with graft loss are likely retransplanted. Although some recipient-and donor-related characteristics were noted to be significant on initial univariate analysis, many of these did not hold significance on the more extensive Cox regression model. Obesity itself is linked to thrombotic complications via decreased fibrinolysis and elevated inflammatory mediators, (4, 5) and abdominal adiposity is a risk factor for the development of PVT even in patients without cirrhosis. (22) However, in this study, the presence of obesity, using BMI as a surrogate, was not associated with changes in graft or patient survival in NASH transplant recipients on adjusted multivariate analysis. Furthermore, although the presence of diabetes was significant on unadjusted multivariate analysis, it did not influence risk for graft loss or mortality after adjusting for significant factors. This suggests in the setting of PVT in NASH transplant recipients, these comorbidities that may or may not exist in concert with NASH do not alter the outcomes. Instead, it is the occurrence of NASH itself in the presence of PVT that influences graft and patient outcomes.
Only older age, higher serum bilirubin, higher DRI, and the presence of a PVT were associated with worse graft failure on adjusted Cox analysis. The impact of donor factors is significant as riskier donor factors are associated with higher morbidity in transplant recipients. For example, there is an increased risk of HAT in recipients with PVT transplanted with organs from donors with a DRI > 1.7. (23) DRI was no longer significant when examining overall deaths in the Cox regression model, representing the role of retransplantation and subsequent patient survival. In the current period where NASH patients are likely to spend longer periods of time on the waiting list compared with other etiologies for transplantation, (1) finding strategies to prevent the development of PVT once a patient is registered may be fruitful. Interestingly, NASH transplant recipients who had documented resolution of PVT by the time of LT had the worst graft and patient outcomes early on in the posttransplant period, which is in contrast to previous studies showing improved survival among recipients transplanted for all indications whose PVT had resolved between listing and transplant. (8, 13) However, the number of patients in this group in the current study may be too small to make clinically meaningful conclusions, and further studies should be carried out to verify these findings.
Currently, there is no consensus on how to manage patients with PVT prior to transplantation. Although administering anticoagulation in the form of vitamin K antagonists assists with preventing further propagation of the clot and parenchymal extinction, while at the same time artificially inflating the MELD score, the decision to use anticoagulation is often center and/ or patient specific. The use of enoxaparin has been shown to prevent development of PVT as well as hepatic decompensation in patients with cirrhosis. (24) Perhaps NASH patients with cirrhosis that are under consideration for transplant should use anticoagulation in the absence of concerning contraindications, ultimately for primary prevention of PVT and treatment of PVT to curb poor transplant outcomes. Future prospective multicenter studies are needed to chronicle the history and potential benefit of employing anticoagulation for primary prevention and secondary prevention/treatment of PVT. Additionally, postoperative management of patients transplanted with PVT is not uniform, as the type of anticoagulant used or duration of optimal anticoagulation in this setting has not been well established.
This study is the largest study examining the effect of PVT on posttransplant outcomes in NASH patients with cirrhosis undergoing LT. However, the study shares many of the limitations associated with retrospective data analysis in which subtle analysis of individual patients is not possible. Despite complications from NASH being a prevalent indication strategies that are not anatomic or do not reverse portal hypertension can result in poorer outcomes. (11, 25) Despite excluding patients with a diagnosis of HCC or incidentally noted HCC at transplant, 15 patients were noted to have HCC or cholangiocarcinoma as a cause of death. Additionally, inclusion of cryptogenic cirrhosis patients with NASH may introduce some inconsistency in the study population. We have included recipients with a diagnosis of cryptogenic cirrhosis with BMI ≥30 kg/m 2 to minimize any false inclusion of etiologies other than possible underlying burnt-out NASH. Previous studies suggest ORIGINAL ARTICLE | 77 that a significant portion of cryptogenic cirrhosis is due to NASH given the similar distribution of the metabolic syndrome and similar outcomes of those individuals. (26) (27) (28) (29) Furthermore, some data from the database may be missing. As previously mentioned, the large sample size is an advantage, but the lack of granularity in the database obscures reasons for cause of death and graft loss. Center-specific data are needed to further understand reasons of graft loss and patient death. Our results echo previous studies showing decreased survival in patients with PVT. (13) (14) (15) (16) However, our results lead to the new finding that NASH transplant recipients with PVT have compromised graft and patient survival compared with NASH transplant recipients without PVT, independent of recipient demographic and comorbidities as well as donor-related factors. Given the increasing trajectory of NASH and rising indication for transplantation, providers will be charged with how to best manage and prevent PVT development in these patients, who at baseline have an increased proinflammatory/prothrombotic risk and, as their disease progresses in severity, are at a heightened probability of developing PVT. This warrants a multicenter approach that can obtain more granular details to understand the natural history of PVT in NASH patients as their disease progresses and treatment strategies to prevent the development and propagation of further clot, which can be deleterious in the setting of transplant.
In conclusion, results of the current study demonstrate that NASH patients with PVT have decreased graft and patient survival independent of recipient and donor factors. Given the growing prevalence of NAFLD and its indication for transplant, strategies are needed to manage PVT and prevent inferior outcomes in the posttransplant setting. Future studies should be carried out to assess the relative impact of post-LT outcome in LT recipients with NASH compared with non-NASH etiologies.
